Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients

Abstract Background Treatment of hyperphosphataemia is the primary goal of chronic kidney disease–mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sev...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2019-07, Vol.34 (7), p.1163-1170
Main Authors: Ketteler, Markus, Sprague, Stuart M, Covic, Adrian C, Rastogi, Anjay, Spinowitz, Bruce, Rakov, Viatcheslav, Walpen, Sebastian, Floege, Jürgen
Format: Article
Language:English
Subjects:
Chelating Agents - therapeutic use
Chronic Kidney Disease-Mineral and Bone Disorder - complications
Chronic Kidney Disease-Mineral and Bone Disorder - metabolism
Chronic Kidney Disease-Mineral and Bone Disorder - therapy
Drug Combinations
Female
Ferric Compounds - therapeutic use
Follow-Up Studies
Humans
Hyperphosphatemia - drug therapy
Hyperphosphatemia - etiology
Male
Middle Aged
ORIGINAL ARTICLES
Parathyroid Hormone - blood
Phosphorus - blood
Renal Dialysis
Sevelamer - therapeutic use
Sucrose - therapeutic use
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Treatment of hyperphosphataemia is the primary goal of chronic kidney disease–mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate (‘sevelamer’) on CKD-MBD indices among dialysis patients with hyperphosphataemia. Methods After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0–3.0 g/day (n = 710) or sevelamer 2.4–14.4 g/day (n = 349) for up to 24 weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed ≥1 year of continuous treatment (n = 549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis. Results Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P 
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfy127